Integrated Filing — IndAS



General information about company

Scrip Code 500087
NSE Symbol CIPLA
MSEI Symbol NOTLISTED
ISIN INE059A01026
Name of company CIPLA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 27-10-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 28-09-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceutical
Start date and time of board meeting 27-10-2026   10:00:00
End date and time of board meeting 27-10-2026   13:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 28-01-2025
Indicate Company website link for updated RPT policy of the Company https://www.cipla.com/sites/default/files/2025-03/Policy-on-Related-Party-Transaction_clean.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 5,06,742.00 10,14,510.00
Other income 14,756.00 39,031.00
Total income 5,21,498.00 10,53,541.00
2 Expenses
(a) Cost of materials consumed 1,12,533.00 2,16,390.00
(b) Purchases of stock-in-trade 63,672.00 1,28,787.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (8,927.00) (6,773.00)
(d) Employee benefit expense 88,141.00 1,79,637.00
(e) Finance costs 592.00 1,160.00
(f) Depreciation, depletion and amortisation expense 18,929.00 35,868.00
(f) Other Expenses
1 Other Expenses 1,40,315.00 2,76,867.00
Total other expenses 1,40,315.00 2,76,867.00
Total expenses 4,15,255.00 8,31,936.00
3 Total profit before exceptional items and tax 1,06,243.00 2,21,605.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 1,06,243.00 2,21,605.00
6 Tax expense
7 Current tax 28,382.00 59,171.00
8 Deferred tax (842.00) (2,485.00)
9 Total tax expenses 27,540.00 56,686.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 78,703.00 1,64,919.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 78,703.00 1,64,919.00
17 Other comprehensive income net of taxes 2,601.00 9,329.00
18 Total Comprehensive Income for the period 81,304.00 1,74,248.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 16,157.00 16,157.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 9.74 20.42
Diluted earnings (loss) per share from continuing operations 9.73 20.4
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 9.74 20.42
Diluted earnings (loss) per share from continuing and discontinued operations 9.73 20.4
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above financial results are prepared in accordance with the Indian Accounting Standard prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 2. The National Pharmaceutical Pricing Authority (“NPPA”) issued several demand notices to the Company commencing from the year 1998 seeking recovery of alleged overcharge regarding scheduled drugs under the Drugs (Prices Control) Orders-1995 (“DPCO”). In 1999 and 2000, the Company filed writ petitions before the Hon’ble Bombay High Court (“Bombay HC”) challenging inclusion of certain drugs under DPCO and challenging the demand notices issued by NPPA demanding payment of alleged overcharged amounts. On 31st August, 2001, by way of its common judgment, the Bombay HC decided the writ petitions in favor of the Company, thereby holding that these drugs do not fall within the purview of DPCO and also quashed the demand notices raised by NPPA. The NPPA appealed the order to the Hon’ble Supreme Court (“SC”). On 1st August, 2003, SC set aside the Bombay HC judgment and remanded the matter to the Bombay HC for being considered afresh by it. Further, the SC stayed recovery of 50% of the alleged overcharged amounts subject to payment of the remaining 50% of the alleged overcharged amounts pending fresh determination by the Bombay HC. Accordingly, in terms of SC’s Judgment the Company deposited an amount of Rs 175.08 Crore with NPPA, representing 50% of the alleged overcharged amounts in respect of demand notices raised till 2003. Post 2003, the Company continued to receive demands (“Subsequent demands”) alleging overcharging. These demands included several duplicate demands. In 2019, the Company applied to the Bombay HC to amend its pleadings to include: (i) subsequent demands (ii) take on record the NPPA/ Government of India’s RTI response on unavailability of any records pertinent to and what should have been the basis for inclusion of these drugs under the DPCO (iii) deduction of trade margin of 16% from outstanding demands (as having not accrued to the Company, as manufacturer) basis the Allahabad HC’s TC Healthcare judgment (iv) re-calculation of interest from the due date of demand notice and (v) duplication of several demands. The Bombay HC vide order dated 23rd February, 2024 allowed the amendment conditional upon the Company depositing 50% of the subsequent demands raised. The Company appealed the Bombay HC order in a special leave petition before the SC. On 19th April, 2024, the SC was pleased to issue notice and the matter is pending to be heard further. Without prejudice to the Company’s position of no amount being due towards the alleged overcharge (principal) or consequential interest, on 15th July 2025 the Company has voluntarily deposited with the NPPA an additional amount of Rs 27.07 Crore towards the principal against certain demand notices. The Company has reviewed all the notices/communications received which are attributable to the Company and are under litigation. After removing duplications as indicated above, the amount covered by the notices/communications aggregates to Rs 2,011 Crore with the principal of Rs 863 Crore and interest of Rs 1,148 Crore. The above demand notices do not include certain demand notices, jointly addressed to Okasa Pharma Private Limited or Okasa Limited (related parties and promoter group companies, collectively “Okasa), and the Company. These pertain to products manufactured by Okasa and marketed by Cipla. The Company responded to these demand notices (amounting to Rs 9.96 Crore), stating that it is not the manufacturer and therefore not liable. These demand notices are also subject matter under Business Transfer Agreement between Okasa and Cipla’s subsidiary which excludes the DPCO liability as part of the business transferred by Okasa to the subsidiary. Further, Okasa has independently challenged these demand notices before the Hon’ble Bombay HC. The Company has been legally advised that it expects a favourable outcome in respect of these matters and therefore no provision is considered necessary in respect of the aforementioned demand notices received till date including demand notices addressed singly/ jointly w.r.t transactions with Okasa. 3. The paid-up equity share capital stands increased to Rs 161.57 Crore (80,78,70,615 equity shares of face value Rs 2 each) upon allotment of 19,350 (half year ended 30th September, 2026- 74,253) equity shares and 5,949 (half year ended 30th September 2026, - 13,731) equity shares of Rs 2 each pursuant to ESOS 2013-A and “Cipla ESAR Scheme 2021” respectively during the quarter ended 30th September 2026. 4. Effective 21st November, 2025, The Government of India had consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. Pursuant to the Company's assessment performed as at 31st December, 2025, the Company recognized an incremental gratuity liability arising from past service cost and an increase in leave liability aggregating Rs 244.37 Crore, primarily due to the revised definition of “wages” applicable to employees and contract labour. Considering the materiality and non-recurring nature of this change, the Company has presented such incremental expenses under “Exceptional Item” in the financial results. 5. During the year ended 31st March, 2026, the Company has recorded an impairment of Rs 31.00 Crore in the financial results in respect of an associate, on account of change in certain business conditions and market dynamics. 6. The Board of Directors of the Company, at its meeting held on 19th March 2026, approved the Scheme of Amalgamation of Inzpera Healthsciences Limited, a wholly owned subsidiary of the Company (the “Transferor Company”), with Cipla Limited (the “Transferee Company” or the “Company”). The Scheme of Amalgamation is subject to the necessary approvals required under the Companies Act, 2013, including the approval of the Hon’ble National Company Law Tribunal (“NCLT”), Mumbai. The Company has filed the Scheme with the Hon’ble NCLT and its approval is awaited. 7. The above results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 27th October, 2026. These results have been subjected to limited review by statutory auditors who have expressed an unmodified review conclusion.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 3,92,421.00
Capital work-in-progress 88,680.00
Investment property 146.00
Goodwill 0.00
Other intangible assets 1,45,169.00
Intangible assets under development 27,931.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 11,63,772.00
Trade receivables, non-current 0.00
Loans, non-current 1,08,680.00
Other non-current financial assets
1 Other financial assets 16,590.00
Total of other non-current financial assets 16,590.00
Total non-current financial assets 12,89,042.00
Deferred tax assets (net) 4,370.00
Other non-current assets
1 Non-current tax assets (net) 47,229.00
2 Other non-current assets 47,598.00
Total of other non-current assets 94,827.00
Total non-current assets 20,42,586.00
2 Current assets
Inventories 4,47,887.00
Current financial asset
Current investments 5,07,993.00
Trade receivables, current 4,20,345.00
Cash and cash equivalents 32,925.00
Bank balance other than cash and cash equivalents 30,399.00
Loans, current 85,663.00
Other current financial assets
Total of other current financial assets 2,33,835.00
Total current financial assets 13,11,160.00
Current tax assets (net) 0.00
Other current assets
1 Other current assets 1,06,124.00
Total of other current assets 1,06,124.00
Total current assets 18,65,171.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 39,07,757.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 16,157.00
Other equity 34,75,015.00
Total equity attributable to owners of parent 34,91,172.00
Non controlling interest
Total equity 34,91,172.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease liabilities 10,355.00
2 Other financial liabilities 13,045.00
Total of other non-current financial liabilities 23,400.00
Total non-current financial liabilities 23,400.00
Provisions, non-current 11,647.00
Deferred tax liabilities (net) 0.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Other non-current liabilities 5,073.00
Total of other non-current liabilities 5,073.00
Total non-current liabilities 40,120.00
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 17,080.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1,71,004.00
Total Trade payable 1,88,084.00
Other current financial liabilities
1 Lease liabilities 3,846.00
2 Other financial liabilities 61,880.00
Total of other current financial liabilities 65,726.00
Total current financial liabilities 2,53,810.00
Other current liabilities 17,492.00
1 Other current liabilities 17,492.00
Total of other current liabilities 17,492.00
Provisions, current 94,431.00
Current tax liabilities (Net) 10,732.00
Deferred government grants, Current 0.00
Total current liabilities 3,76,465.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 4,16,585.00
Total equity and liabilites 39,07,757.00
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block

Textual Information(1) Notes: i. The above statement of cash flow has been prepared under the 'Indirect method' as set out in Indian Accounting Standard (Ind AS) 7-Statement of Cash Flows. ii. Purchase and sale of property, plant and equipment represents additions and deletions to property, plant and equipment and investment properties adjusted for movement of capital work in progress, capital advances, capital creditors during the period.



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss (306.00) 2,209.00
Total Amount of items that will not be reclassified to profit and loss (306.00) 2,209.00
2 Income tax relating to items that will not be reclassified to profit or loss (77.00) 556.00
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit or loss 3,782.00 10,258.00
Total Amount of items that will be reclassified to profit and loss 3,782.00 10,258.00
4 Income tax relating to items that will be reclassified to profit or loss 952.00 2,582.00
5 Total Other comprehensive income 2,601.00 9,329.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 2,21,605.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 1,160.00
Adjustments for decrease (increase) in inventories (12,516.00)
Adjustments for decrease (increase) in trade receivables, current (86,693.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 17,169.00
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (19,466.00)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 342.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 35,868.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (2,648.00)
Adjustments for dividend income 0.00
Adjustments for interest income 14,970.00
Adjustments for share-based payments 1,806.00
Adjustments for fair value losses (gains) (164.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (19,034.00)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 84.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (99,062.00)
Net cash flows from (used in) operations 1,22,543.00
Dividends received (1,901.00)
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 48,282.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 72,360.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 78,025.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 391.00
Purchase of property, plant and equipment 52,899.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 7,575.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 960.00
Cash advances and loans made to other parties 12,000.00
Cash receipts from repayment of advances and loans made to other parties 5,700.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 1,901.00
Interest received 15,982.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 1,71,432.00
Net cash flows from (used in) investing activities 43,947.00
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 1.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 1,060.00
Payments of lease liabilities 1,378.00
Dividends paid 1,05,020.00
Interest paid 779.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (1,08,236.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 8,071.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents (26.00)
Net increase (decrease) in cash and cash equivalents 8,045.00
Cash and cash equivalents cash flow statement at beginning of period 24,880.00
Cash and cash equivalents cash flow statement at end of period 32,925.00





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Cipla Limited AMPIN Energy Green Eleven Private Limited Associate Any other transaction Electricity charges paid 1,200.00 Approved 268.00 0.00 0.00
2 Cipla Limited AMPIN Power Systems Private Limited Associate Any other transaction Electricity charges paid 2,000.00 Approved 335.00 0.00 0.00
3 Cipla Limited Aspergen Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Received 10,000.00 Approved 157.00 0.00 0.00
4 Cipla Limited Aspergen Inc. Holding-Subsidiary Sale of goods or services 7,500.00 Approved 350.00 0.00 0.00
5 Cipla Limited Aspergen Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 2,000.00 Approved 30.00 0.00 0.00
6 Cipla Limited Aspergen Limited Holding-Subsidiary Investment 39,102.00 Approved 30,361.00 0.00 0.00
7 Cipla Limited Breathe Free Lanka (Private) Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 11.00 0.00 0.00
8 Cipla Limited Breathe Free Lanka (Private) Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 10,501.00 0.00 0.00
9 Cipla Limited Cipla (China) Pharmaceutical Co., Ltd. Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 471.00 0.00 0.00
10 Cipla Limited Cipla (China) Pharmaceutical Co., Ltd. Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 656.00 0.00 0.00
11 Cipla Limited Cipla (China) Pharmaceutical Co., Ltd. Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 10.00 0.00 0.00
12 Cipla Limited Cipla (EU) Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 57.00 0.00 0.00
13 Cipla Limited Cipla (EU) Limited Holding-Subsidiary Investment 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 47,664.00 0.00 0.00
14 Cipla Limited Cipla (EU) Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 748.00 0.00 0.00
15 Cipla Limited Cipla (EU) Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 9,017.00 0.00 0.00
16 Cipla Limited Cipla (Jiangsu) Pharmaceutical Co., Ltd. Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 116.00 0.00 0.00
17 Cipla Limited Cipla (Jiangsu) Pharmaceutical Co., Ltd. Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 84.00 0.00 0.00
18 Cipla Limited Cipla (Jiangsu) Pharmaceutical Co., Ltd. Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 650.00 0.00 0.00
19 Cipla Limited Cipla Australia Pty Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 4.00 0.00 0.00
20 Cipla Limited Cipla Australia Pty Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 339.00 0.00 0.00
21 Cipla Limited Cipla Australia Pty Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 703.00 0.00 0.00
22 Cipla Limited Cipla Brasil lmportadora E Distribuidora De Medicamentos Ltda Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,350.00 0.00 0.00
23 Cipla Limited Cipla Brasil lmportadora E Distribuidora De Medicamentos Ltda Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 3.00 0.00 0.00
24 Cipla Limited Cipla Brasil lmportadora E Distribuidora De Medicamentos Ltda Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 890.00 0.00 0.00
25 Cipla Limited Cipla Colombia SAS Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 2.00 0.00 0.00
26 Cipla Limited Cipla Colombia SAS Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 3,396.00 0.00 0.00
27 Cipla Limited Cipla Digital Health Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1.00 0.00 0.00
28 Cipla Limited Cipla Digital Health Limited Holding-Subsidiary Any other transaction Royalty Income 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 0.00 0.00 0.00
29 Cipla Limited Cipla Digital Health Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 830.00 0.00 0.00
30 Cipla Limited Cipla Digital Health Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 99.00 0.00 0.00
31 Cipla Limited Cipla Europe NV Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,145.00 0.00 0.00
32 Cipla Limited Cipla Europe NV Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 5.00 0.00 0.00
33 Cipla Limited Cipla Europe NV Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 10,297.00 0.00 0.00
34 Cipla Limited Cipla Foundation Entity over which a KMP or a relative of a KMP is able to exercise significant influence/control Any other transaction CSR and CER Contributions 11,000.00 Approved 4,360.00 0.00 0.00
35 Cipla Limited Cipla Gulf FZ – LLC Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 128.00 0.00 0.00
36 Cipla Limited Cipla Gulf FZ – LLC Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 2.00 0.00 0.00
37 Cipla Limited Cipla Gulf FZ – LLC Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 4,355.00 0.00 0.00
38 Cipla Limited Cipla Health Limited Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 15.00 0.00 0.00
39 Cipla Limited Cipla Health Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 516.00 0.00 0.00
40 Cipla Limited Cipla Health Limited Holding-Subsidiary Any other transaction Technical Know-How/Fees received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1.00 0.00 0.00
41 Cipla Limited Cipla Health Limited Holding-Subsidiary Any other transaction Royalty Income 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,436.00 0.00 0.00
42 Cipla Limited Cipla Health Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 4,982.00 0.00 0.00
43 Cipla Limited Cipla Health Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 3,727.00 0.00 0.00
44 Cipla Limited Cipla Holding B.V. Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 2.00 0.00 0.00
45 Cipla Limited Cipla Holding B.V. Holding-Subsidiary Any other transaction Testing and Analysis Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 213.00 0.00 0.00
46 Cipla Limited Cipla Holding B.V. Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1.00 0.00 0.00
47 Cipla Limited Cipla Kenya Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 0.00 0.00 0.00
48 Cipla Limited Cipla Kenya Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 504.00 0.00 0.00
49 Cipla Limited Cipla Kenya Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,532.00 0.00 0.00
50 Cipla Limited Cipla Limited Employees Gratuity Fund Post Employment Benefit Trust Any other transaction Contribution to Gratuity Fund (Net) 20,000.00 Approved 490.00 0.00 0.00
51 Cipla Limited Cipla Limited Employees Provident Fund Post Employment Benefit Trust Any other transaction Contribution to Provident Fund 19,000.00 Approved 3,595.00 0.00 0.00
52 Cipla Limited Cipla Limited Employees Provident Fund Post Employment Benefit Trust Any other transaction Reimbursement Charges Paid 100.00 Approved 10.00 0.00 0.00
53 Cipla Limited Cipla Malaysia Sdn. Bhd. Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 2.00 0.00 0.00
54 Cipla Limited Cipla Malaysia Sdn. Bhd. Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 596.00 0.00 0.00
55 Cipla Limited Cipla Malaysia Sdn. Bhd. Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 0.00 0.00 0.00
56 Cipla Limited Cipla Maroc S.A. Holding-Subsidiary Any other transaction Reimbursement Charges Received 400.00 Approved 21.00 0.00 0.00
57 Cipla Limited Cipla Maroc S.A. Holding-Subsidiary Any other transaction Royalty Income 500.00 Approved 165.00 0.00 0.00
58 Cipla Limited Cipla Maroc S.A. Holding-Subsidiary Sale of fixed assets 60.00 Approved 39.00 0.00 0.00
59 Cipla Limited Cipla Maroc S.A. Holding-Subsidiary Sale of goods or services 11,900.00 Approved 1,919.00 0.00 0.00
60 Cipla Limited Cipla Medpro Manufacturing Proprietary Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 100.00 Approved 5.00 0.00 0.00
61 Cipla Limited Cipla Medpro Manufacturing Proprietary Limited Holding-Subsidiary Any other transaction Royalty Income 9,000.00 Approved 2,041.00 0.00 0.00
62 Cipla Limited Cipla Medpro Manufacturing Proprietary Limited Holding-Subsidiary Sale of goods or services 5,200.00 Approved 56.00 0.00 0.00
63 Cipla Limited Cipla Medpro South Africa Proprietary Limited Holding-Subsidiary Interest received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 2,357.00 0.00 0.00
64 Cipla Limited Cipla Medpro South Africa Proprietary Limited Holding-Subsidiary Any other transaction Loan Repaid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 5,700.00 0.00 0.00
65 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 344.00 0.00 0.00
66 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Any other transaction Rent Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 67.00 0.00 0.00
67 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Any other transaction Royalty Income 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,790.00 0.00 0.00
68 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 526.00 0.00 0.00
69 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 12,044.00 0.00 0.00
70 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 3,519.00 0.00 0.00
71 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 486.00 0.00 0.00
72 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Interest received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 751.00 0.00 0.00
73 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Any other transaction Loan given 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 12,000.00 0.00 0.00
74 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Purchase of fixed assets 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 41.00 0.00 0.00
75 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 471.00 0.00 0.00
76 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Sale of fixed assets 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 0.00 0.00 0.00
77 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 480.00 0.00 0.00
78 Cipla Limited Cipla Select Proprietary Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 4,034.00 0.00 0.00
79 Cipla Limited Cipla USA Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 17,296.00 0.00 0.00
80 Cipla Limited Cipla USA Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1.00 0.00 0.00
81 Cipla Limited Cipla USA Inc. Holding-Subsidiary Interest received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 3,036.00 0.00 0.00
82 Cipla Limited Cipla USA Inc. Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 202.00 0.00 0.00
83 Cipla Limited Cipla USA Inc. Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 84,857.00 0.00 0.00
84 Cipla Limited CiplaRna GmbH Holding-Subsidiary Any other transaction Testing and Analysis Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 947.00 0.00 0.00
85 Cipla Limited Clean Max Auriga Power LLP Associate Any other transaction Electricity charges paid 1,100.00 Approved 392.00 0.00 0.00
86 Cipla Limited Exelan Pharmaceuticals Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,096.00 0.00 0.00
87 Cipla Limited Exelan Pharmaceuticals Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 3.00 0.00 0.00
88 Cipla Limited Exelan Pharmaceuticals Inc. Holding-Subsidiary Any other transaction Royalty Income 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 76,096.00 0.00 0.00
89 Cipla Limited Exelan Pharmaceuticals Inc. Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,020.00 0.00 0.00
90 Cipla Limited GoApptiv Private Limited Associate Any other transaction Reimbursement Charges Paid 4,000.00 Approved 328.00 0.00 0.00
91 Cipla Limited GoApptiv Private Limited Associate Purchase of goods or services 4,000.00 Approved 1,457.00 0.00 0.00
92 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Any other transaction Processing charges paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 2,803.00 0.00 0.00
93 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 10.00 0.00 0.00
94 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Purchase of fixed assets 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 477.00 0.00 0.00
95 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 6,945.00 0.00 0.00
96 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Sale of fixed assets 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1.00 0.00 0.00
97 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 6,193.00 0.00 0.00
98 Cipla Limited Icaltech Innovations Private Limited Associate Purchase of goods or services 100.00 Approved 2.00 0.00 0.00
99 Cipla Limited Icaltech Innovations Private Limited Associate Sale of goods or services 200.00 Approved 6.00 0.00 0.00
100 Cipla Limited InvaGen Pharmaceuticals Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,385.00 0.00 0.00
101 Cipla Limited InvaGen Pharmaceuticals Inc. Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 106.00 0.00 0.00
102 Cipla Limited InvaGen Pharmaceuticals Inc. Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 85.00 0.00 0.00
103 Cipla Limited InvaGen Pharmaceuticals Inc. Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 482.00 0.00 0.00
104 Cipla Limited Inzpera Healthsciences Limited Holding-Subsidiary Interest received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 54.00 0.00 0.00
105 Cipla Limited Inzpera Healthsciences Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 2,732.00 0.00 0.00
106 Cipla Limited Inzpera Healthsciences Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 31.00 0.00 0.00
107 Cipla Limited Jay Precision Pharmaceuticals Private Limited Holding-Subsidiary Purchase of goods or services 22,000.00 Approved 8,710.00 0.00 0.00
108 Cipla Limited Jay Precision Products (India) Private Limited Related party of a subsidiary Purchase of fixed assets 6,000.00 Approved 12.00 0.00 0.00
109 Cipla Limited Jay Precision Products (India) Private Limited Related party of a subsidiary Purchase of goods or services 4,000.00 Approved 53.00 0.00 0.00
110 Cipla Limited Kamil Hamied Non-executive Director Any other transaction Sitting Fees/Commission and Other Benefits 130.00 Approved 130.00 0.00 0.00
111 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Any other transaction Processing charges paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 3,159.00 0.00 0.00
112 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Any other transaction Processing charges received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 164.00 0.00 0.00
113 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 15.00 0.00 0.00
114 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 25.00 0.00 0.00
115 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 17,193.00 0.00 0.00
116 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Sale of fixed assets 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 28.00 0.00 0.00
117 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 2,729.00 0.00 0.00
118 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Any other transaction Processing charges paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1,721.00 0.00 0.00
119 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 5.00 0.00 0.00
120 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Purchase of fixed assets 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 0.00 0.00 0.00
121 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 118.00 0.00 0.00
122 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 13.00 0.00 0.00
123 Cipla Limited Medpro Pharmaceutica Proprietary Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 334.00 0.00 0.00
124 Cipla Limited Medpro Pharmaceutica Proprietary Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 37,061.00 0.00 0.00
125 Cipla Limited Mexicip, S.A. de C.V. Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 237.00 0.00 0.00
126 Cipla Limited Mirren Proprietary Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 27.00 0.00 0.00
127 Cipla Limited Mirren Proprietary Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 2.00 0.00 0.00
128 Cipla Limited Sitec Labs Limited Holding-Subsidiary Any other transaction Reimbursement Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 238.00 0.00 0.00
129 Cipla Limited Sitec Labs Limited Holding-Subsidiary Any other transaction Reimbursement Charges Received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 36.00 0.00 0.00
130 Cipla Limited Sitec Labs Limited Holding-Subsidiary Any other transaction Testing and Analysis Charges Paid 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 8,204.00 0.00 0.00
131 Cipla Limited Sitec Labs Limited Holding-Subsidiary Interest received 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 150.00 0.00 0.00
132 Cipla Limited Sitec Labs Limited Holding-Subsidiary Purchase of fixed assets 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 1.00 0.00 0.00
133 Cipla Limited Sitec Labs Limited Holding-Subsidiary Purchase of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 5.00 0.00 0.00
134 Cipla Limited Sitec Labs Limited Holding-Subsidiary Sale of fixed assets 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 0.00 0.00 0.00
135 Cipla Limited Sitec Labs Limited Holding-Subsidiary Sale of goods or services 0.00 Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 223.00 0.00 0.00
136 Cipla Limited Societe Marocaine De Cooperation Pharmaceutique (Cooper) Related party of a subsidiary Sale of goods or services 5,000.00 Approved 1,948.00 0.00 0.00
137 Cipla Limited Stempeutics Research Private Limited Associate Any other transaction Reimbursement Charges Paid 450.00 Approved 3.00 0.00 0.00
138 Cipla Limited Stempeutics Research Private Limited Associate Any other transaction Royalty Paid 100.00 Approved 3.00 0.00 0.00
139 Cipla Limited Stempeutics Research Private Limited Associate Purchase of goods or services 2,050.00 Approved 385.00 0.00 0.00
140 Cipla Limited Veritas Legal Firm in which director, manager or his relative is a partner Purchase of goods or services 400.00 Approved 182.00 0.00 0.00
141 Cipla Limited Y K Hamied Non-executive Chairman Any other transaction Sitting Fees/Commission and Other Benefits 128.00 Approved 128.00 0.00 0.00
142 Cipla Limited Y K Hamied Non-executive Chairman Any other transaction Rent Received 0.00 Approved 0.00 0.00 0.00
143 Cipla Limited Cipla Medpro South Africa Proprietary Limited Holding-Subsidiary Loan 0.00 Not applicable 0.00 55,225.00 52,628.00 Loan 0 0 Unsecured Working Capital/Capital Expenditure Requirement Textual Information(1)
144 Cipla Limited Cipla USA Inc. Holding-Subsidiary Loan 0.00 Not applicable 0.00 1,13,802.00 1,14,990.00 Loan 0 0 Unsecured Working Capital/Capital Expenditure Requirement Textual Information(2)
145 Cipla Limited Sitec Labs Limited Holding-Subsidiary Loan 0.00 Not applicable 0.00 4,200.00 4,200.00 Loan 0 0 Unsecured Working Capital/Capital Expenditure Requirement Textual Information(3)
146 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Loan 0.00 Not applicable 0.00 9,000.00 21,318.00 Loan 7.2500 0 Unsecured Working Capital/Capital Expenditure Requirement Textual Information(4)
147 Cipla Limited Inzpera Healthsciences Limited Holding-Subsidiary Loan 0.00 Not applicable 0.00 1,459.00 1,514.00 Loan 7.600 0 Unsecured Working Capital/Capital Expenditure Requirement Textual Information(5)
148 Cipla Limited Achira Labs Private Limited Associate Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 3.00 3.00
149 Cipla Limited AMPIN Energy Green Eleven Private Limited Associate Any other transaction Trade and Other payable 0.00 Not applicable 0.00 277.00 108.00
150 Cipla Limited AMPIN Power Systems Private Limited Associate Any other transaction Trade and Other payable 0.00 Not applicable 0.00 284.00 88.00
151 Cipla Limited Aspergen Inc. Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 1,228.00 1,750.00
152 Cipla Limited Aspergen Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 0.00 30.00
153 Cipla Limited Breathe Free Lanka (Private) Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 3,745.00 9,024.00
154 Cipla Limited Cipla (China) Pharmaceutical Co., Ltd. Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 443.00 1,277.00
155 Cipla Limited Cipla (EU) Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 5,000.00 3,497.00
156 Cipla Limited Cipla (Jiangsu) Pharmaceutical Co., Ltd. Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 125.00 263.00
157 Cipla Limited Cipla Australia Pty Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 2,011.00 641.00
158 Cipla Limited Cipla Brasil lmportadora E Distribuidora De Medicamentos Ltda Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 3,081.00 3,135.00
159 Cipla Limited Cipla Colombia SAS Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 3,305.00 4,019.00
160 Cipla Limited Cipla Digital Health Limited Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 382.00 337.00
161 Cipla Limited Cipla Europe NV Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 10,073.00 267.00
162 Cipla Limited Cipla Gulf FZ – LLC Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 (943.00) 784.00
163 Cipla Limited Cipla Health Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 3,783.00 1,635.00
164 Cipla Limited Cipla Holding B.V. Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 1,956.00 2,171.00
165 Cipla Limited Cipla Kenya Limited Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 921.00 319.00
166 Cipla Limited Cipla Limited Employees Gratuity Fund Post Employment Benefit Trust Any other transaction Payable to Gratuity Trust 0.00 Not applicable 0.00 1,900.00 1,698.00
167 Cipla Limited Cipla Limited Employees Provident Fund Post Employment Benefit Trust Any other transaction Payable to Provident Fund Trust 0.00 Not applicable 0.00 2,899.00 3,127.00
168 Cipla Limited Cipla Malaysia Sdn. Bhd. Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 310.00 310.00
169 Cipla Limited Cipla Maroc S.A. Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 4,790.00 2,527.00
170 Cipla Limited Cipla Medpro Manufacturing Proprietary Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 644.00 2,200.00
171 Cipla Limited Cipla Medpro South Africa Proprietary Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 2,697.00 0.00
172 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 8,150.00 6,729.00
173 Cipla Limited Cipla Pharma and Life Sciences Limited Holding-Subsidiary Any other transaction Capital Creditors 0.00 Not applicable 0.00 63.00 0.00
174 Cipla Limited CiplaRna GmbH Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 637.00 415.00
175 Cipla Limited Cipla Select Proprietary Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 5,523.00 8,114.00
176 Cipla Limited Cipla USA Inc. Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 62,670.00 97,340.00
177 Cipla Limited Clean Max Auriga Power LLP Associate Any other transaction Trade and Other payable 0.00 Not applicable 0.00 61.00 25.00
178 Cipla Limited Societe Marocaine De Cooperation Pharmaceutique (Cooper) Related party of a subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 1,016.00 1,695.00
179 Cipla Limited Exelan Pharmaceuticals Inc. Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 34,971.00 36,796.00
180 Cipla Limited GoApptiv Private Limited Associate Any other transaction Trade and Other payable 0.00 Not applicable 0.00 128.00 321.00
181 Cipla Limited Goldencross Pharma Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 (1,543.00) 1,980.00
182 Cipla Limited Icaltech Innovations Private Limited Associate Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 13.00 20.00
183 Cipla Limited InvaGen Pharmaceuticals Inc. Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 (3,189.00) 768.00
184 Cipla Limited Jay Precision Pharmaceuticals Private Limited Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 1,822.00 3,516.00
185 Cipla Limited Jay Precision Products (India) Private Limited Related party of a subsidiary Any other transaction Capital Advance 0.00 Not applicable 1,444.00 1,322.00 2,765.00
186 Cipla Limited Kamil Hamied Non-executive Director Any other transaction Commission and Other Benefits payable 0.00 Not applicable 0.00 153.00 125.00
187 Cipla Limited Medispray Laboratories Private Limited Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 4,244.00 3,511.00
188 Cipla Limited Meditab Specialities Limited Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 776.00 402.00
189 Cipla Limited Medpro Pharmaceutica Proprietary Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 26,537.00 33,859.00
190 Cipla Limited Mexicip, S.A. de C.V. Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 526.00 391.00
191 Cipla Limited Mirren Proprietary Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 16.00 37.00
192 Cipla Limited Sitec Labs Limited Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 1,049.00 2,290.00
193 Cipla Limited Stempeutics Research Private Limited Associate Any other transaction Trade and Other payable 0.00 Not applicable 0.00 23.00 94.00
194 Cipla Limited Veritas Legal Firm in which director, manager or his relative is a partner Any other transaction Trade and Other payable 0.00 Not applicable 0.00 68.00 82.00
195 Cipla Limited Y K Hamied Non-executive Chairman Any other transaction Commission and Other Benefits payable 0.00 Not applicable 0.00 153.00 125.00
196 Cipla Limited Cipla Foundation Entity over which a KMP or a relative of a KMP is able to exercise significant influence/control Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 509.00 0.00
197 Cipla Limited Cipla Pharmaceuticals Limited Holding-Subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 2,474.00 1,340.00
198 Cipla Limited Inzpera Healthsciences Limited Holding-Subsidiary Any other transaction Trade and Other receivable 0.00 Not applicable 0.00 72.00 181.00
199 Cipla Limited Jay Precision Products (India) Private Limited Related party of a subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 54.00 70.00
200 Cipla Limited Synpure Labs India Private Limited Related party of a subsidiary Any other transaction Trade and Other payable 0.00 Not applicable 0.00 0.00 0.00
201 Cipla Pharmaceuticals Limited Cipla Foundation Related party of listed entity Any other transaction CER contribution 0.00 Not Applicable 131.00 0.00 0.00
202 Jay Precision Pharmaceuticals Private Limited Cipla Foundation Related party of listed entity Any other transaction CSR Contribution 0.00 Not Applicable 54.00 0.00 0.00
203 Jay Precision Pharmaceuticals Private Limited Jay Precision Products (India) Private Limited Private company in which a director/relative is a member/director Purchase of fixed assets 4,000.00 Approved 751.00 0.00 0.00
204 Jay Precision Pharmaceuticals Private Limited Jay Precision Products (India) Private Limited Private company in which a director/relative is a member/director Any other transaction Capital Advance 0.00 Not Applicable 120.00 0.00 0.00
205 Jay Precision Pharmaceuticals Private Limited Jay Precision Products (India) Private Limited Private company in which a director/relative is a member/director Any other transaction Rent Received 100.00 Approved 8.00 0.00 0.00
206 Jay Precision Pharmaceuticals Private Limited Jay Precision Products (India) Private Limited Private company in which a director/relative is a member/director Sale of goods or services 100.00 Approved 3.00 0.00 0.00
207 Jay Precision Pharmaceuticals Private Limited Jay Precision Products (India) Private Limited Private company in which a director/relative is a member/director Purchase of goods or services 300.00 Approved 14.00 0.00 0.00
208 Jay Precision Pharmaceuticals Private Limited Medispray Laboratories Private Limited Subsidiaries Sale of goods or services 6,000.00 Approved 414.00 0.00 0.00
209 Jay Precision Pharmaceuticals Private Limited Jay Precision Pharmaceuticals Employees Group Gratuity Trust Post employment benefit trust Any other transaction Contribution to Gratuity Fund 0.00 Not Applicable 43.00 0.00 0.00
210 Jay Precision Pharmaceuticals Private Limited Ampin Energy C&I Eighteen Private Limited Associate Any other transaction Electricity charges paid 0.00 Not Applicable 53.00 0.00 0.00
211 Meditab Specialities Limited Medispray Laboratories Private Limited Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 1.00 0.00 0.00
212 Meditab Specialities Limited Cipla Foundation Related party of listed entity Any other transaction CSR Contribution 0.00 Not Applicable 9.00 0.00 0.00
213 Meditab Specialities Limited Meditab Specialities Limited Employees Comprehensive Gratuity Scheme Post employment benefit trust Any other transaction Withdrawal from Gratuity Fund 800.00 Approved 1.00 0.00 0.00
214 Medispray Laboratories Private Limited Cipla Maroc SA Subsidiaries Sale of goods or services 6,000.00 Approved 1,414.00 0.00 0.00
215 Medispray Laboratories Private Limited Meditab Specialities Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 5.00 0.00 0.00
216 Medispray Laboratories Private Limited Jay Precision Products (India) Private Limited Related party of a subsidiary Purchase of fixed assets 10,000.00 Approved 2,900.00 0.00 0.00
217 Medispray Laboratories Private Limited Jay Precision Products (India) Private Limited Related party of a subsidiary Purchase of goods or services 500.00 Approved 19.00 0.00 0.00
218 Medispray Laboratories Private Limited Jay Precision Products (India) Private Limited Related party of a subsidiary Any other transaction Capital Advance 0.00 Not Applicable 408.00 0.00 0.00
219 Medispray Laboratories Private Limited Cipla Foundation Related party of listed entity Any other transaction CSR Contribution 0.00 Not Applicable 34.00 0.00 0.00
220 Medispray Laboratories Private Limited Medispray Laboratories Private Limited Employees Comprehensive Gratuity Scheme Post employment benefit trust Any other transaction Withdrawal from Gratuity Fund 0.00 Not Applicable 2.00 0.00 0.00
221 Goldencross Pharma Limited Cipla Health Limited Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 796.00 0.00 0.00
222 Goldencross Pharma Limited Jay Precision Products (India) Private Limited Related Party of a Subsidary Sale of goods or services 0.00 Not Applicable 5.00 0.00 0.00
223 Goldencross Pharma Limited Cipla Foundation Related party of listed entity Any other transaction CSR Contribution 0.00 Not Applicable 20.00 0.00 0.00
224 Goldencross Pharma Limited Goldencross Pharma Limited Employees Group Gratuity Fund Post Employment Benefit Trust Any other transaction Withdrawal from Gratuity Fund 0.00 Not Applicable 7.00 0.00 0.00
225 Sitec Labs Limited Cipla USA Inc. Subsidiaries Any other transaction Testing and Analysis Charges Received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 11.00 0.00 0.00
226 Sitec Labs Limited Medispray Laboratories Private Limited Subsidiaries Any other transaction Testing and Analysis Charges Received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 2.00 0.00 0.00
227 Sitec Labs Limited Meditab Specialities Limited Subsidiaries Any other transaction Testing and Analysis Charges Received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 0.00 0.00 0.00
228 Sitec Labs Limited Cipla Foundation Related party of listed entity Any other transaction CSR Contribution 0.00 Not Applicable 22.00 0.00 0.00
229 Sitec Labs Limited Sitec Labs Private Limited Employees Comprehensive Gratuity Scheme Post employment benefit trust Any other transaction Withdrawal from Gratuity Fund 1,700.00 Approved 8.00 0.00 0.00
230 Cipla Health Limited Cipla Pharma and Life Sciences Limited Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 10.00 0.00 0.00
231 Cipla Health Limited Cipla Pharma and Life Sciences Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 537.00 0.00 0.00
232 Cipla Health Limited Cipla Foundation Related party of listed entity Any other transaction CSR Contribution 0.00 Not Applicable 110.00 0.00 0.00
233 Cipla Health Limited Cipla Health Limited Employees Gratuity Scheme Post employment benefit trust Any other transaction Contribution to Gratuity Fund 0.00 Not Applicable 202.00 0.00 0.00
234 Cipla Health Limited Cipla Limited Employees Gratuity Fund Post employment benefit trust Any other transaction Contribution to Gratuity Fund 0.00 Not Applicable 55.00 0.00 0.00
235 Cipla Pharma and Life Sciences Limited Cipla Foundation Related party of listed entity Any other transaction CSR Contribution 0.00 Not Applicable 346.00 0.00 0.00
236 Cipla Pharma and Life Sciences Limited Cipla Pharma and Life Sciences Limited Employees Gratuity Fund Post Employment Benefit Trust Any other transaction Contribution to Gratuity Fund 0.00 Not Applicable 39.00 0.00 0.00
237 Cipla Pharma and Life Sciences Limited GoApptiv Private Limited Associate of listed entity Any other transaction Processing Charges Paid 0.00 Not Applicable 1.00 0.00 0.00
238 Actor Pharma Proprietary Limited Cipla Select Proprietary Limited Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 294.00 0.00 0.00
239 Actor Pharma Proprietary Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 975.00 0.00 0.00
240 Cipla-Medpro Distribution Centre Proprietary Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Any other transaction Distribution fee income 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 5,215.00 0.00 0.00
241 Cipla Medpro Manufacturing (Pty) Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Sale of goods or services 60,000.00 Approved 19,084.00 0.00 0.00
242 Cipla Medpro Manufacturing (Pty) Limited Cipla Select Proprietary Limited Subsidiaries Sale of goods or services 3,000.00 Approved 1,167.00 0.00 0.00
243 Cipla Medpro Manufacturing (Pty) Limited The Cipla Foundation, South Africa Entities over which the company is able to exercise significant influence/Control Any other transaction CSR Contribution 0.00 Not Applicable 677.00 0.00 0.00
244 Cipla Medpro South Africa Proprietary Limited Cipla Medpro Manufacturing (Pty) Limited Subsidiaries Any other transaction Reimbursement charges received 2,000.00 Approved 125.00 0.00 0.00
245 Cipla Medpro South Africa Proprietary Limited Brandmed (Pty) Limited Associate Interest received 0.00 Not Applicable 106.00 0.00 0.00
246 Cipla Medpro South Africa Proprietary Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Interest received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 2,467.00 0.00 0.00
247 Cipla Select Proprietary Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 285.00 0.00 0.00
248 Cipla-Medpro (Pty) Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Any other transaction Royalty Income 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 1,382.00 0.00 0.00
249 Cipla-Medpro (Pty) Limited Cipla Select Proprietary Limited Subsidiaries Any other transaction Royalty Income 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 175.00 0.00 0.00
250 Medpro Pharmaceutica (Pty) Limited Cipla Select Proprietary Limited Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 1,175.00 0.00 0.00
251 Medpro Pharmaceutica (Pty) Limited Cipla-Medpro Distribution Centre Proprietary Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 49.00 0.00 0.00
252 Medpro Pharmaceutica (Pty) Limited The Cipla Foundation, South Africa Entities over which the company is able to exercise significant influence/Control Any other transaction CSR Contribution 0.00 Not Applicable 14.00 0.00 0.00
253 Medpro Pharmaceutica (Pty) Limited Cipla Select Proprietary Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 369.00 0.00 0.00
254 Medpro Pharmaceutica (Pty) Limited Cipla Select Proprietary Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 1,979.00 0.00 0.00
255 Medpro Pharmaceutica (Pty) Limited Cipla Medpro South Africa Proprietary Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 233.00 0.00 0.00
256 Medpro Pharmaceutica (Pty) Limited Cipla Medpro Manufacturing (Pty) Limited Subsidiaries Any other transaction Reimbursement charges received 5,000.00 Approved 1,719.00 0.00 0.00
257 Medpro Pharmaceutica (Pty) Limited Cipla Medpro Manufacturing (Pty) Limited Subsidiaries Any other transaction Reimbursement charges paid 12,000.00 Approved 4,379.00 0.00 0.00
258 Medpro Pharmaceutica (Pty) Limited Mirren Proprietary Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 16.00 0.00 0.00
259 Medpro Pharmaceutica (Pty) Limited Cipla Kenya Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 14.00 0.00 0.00
260 Medpro Pharmaceutica (Pty) Limited Cipla-Medpro (Pty) Limited Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 528.00 0.00 0.00
261 Mirren Proprietary Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 5,437.00 0.00 0.00
262 Mirren Proprietary Limited Cipla Medpro Manufacturing (Pty) Limited Subsidiaries Sale of goods or services 500.00 Approved 6.00 0.00 0.00
263 Cipla USA Inc. InvaGen Pharmaceuticals Inc. Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 6,300.00 0.00 0.00
264 Cipla USA Inc. Exelan Pharmaceuticals Inc. Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 528.00 0.00 0.00
265 Cipla USA Inc. Aspergen Inc. Subsidiaries Sale of goods or services 5,000.00 Approved 45.00 0.00 0.00
266 Invagen Pharmaceuticals Inc. Cipla USA Inc. Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 6,794.00 0.00 0.00
267 Invagen Pharmaceuticals Inc. Cipla USA Inc. Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 14,974.00 0.00 0.00
268 Invagen Pharmaceuticals Inc. Exelan Pharmaceuticals Inc. Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 20,900.00 0.00 0.00
269 Invagen Pharmaceuticals Inc. Cipla Therapeutics Inc. Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 2.00 0.00 0.00
270 Exelan Pharmaceuticals Inc. InvaGen Pharmaceuticals Inc. Subsidiaries Any other transaction Reimbursement charges Received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 241.00 0.00 0.00
271 Aspergen Inc. Kemwell Biopharma Private Limited Private company in which a director/relative is a member/director Purchase of goods or services 10,000.00 Approved 2,684.00 0.00 0.00
272 Aspergen Inc. Kemwell Biopharma Private Limited Private company in which a director/relative is a member/director Any other transaction Reimbursement charges paid 8,000.00 Approved 4,753.00 0.00 0.00
273 Aspergen Limited Cipla (EU) Limited Subsidiaries Any other transaction Purchase of stake in Aspergen Inc 17,645.00 Approved 17,392.00 0.00 0.00
274 Aspergen Limited Kemwell Biopharma UK Limited Investing company Any other transaction Purchase of stake in Aspergen Inc 11,763.00 Approved 11,595.00 0.00 0.00
275 Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda Cipla Gulf FZ-LLC Subsidiaries Purchase of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 302.00 0.00 0.00
276 Cipla Europe NV CiplaRna GmbH Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 2.00 0.00 0.00
277 Cipla (EU) Limited Cipla Europe NV Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 410.00 0.00 0.00
278 Cipla (EU) Limited Cipla (Jiangsu) Pharmaceutical Co., Ltd. Subsidiaries Interest received 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 355.00 0.00 0.00
279 Cipla (EU) Limited Mexicip S.A. de C.V. Subsidiaries Interest received 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 13.00 0.00 0.00
280 Cipla Holding B.V. Cipla Europe NV Subsidiaries Any other transaction Testing and Analysis Charges Received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 751.00 0.00 0.00
281 Cipla Holding B.V. Cipla (EU) Limited Subsidiaries Any other transaction Testing and Analysis Charges Received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 739.00 0.00 0.00
282 Cipla Gulf FZ – LLC Cipla Middle East Company Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 238.00 0.00 0.00
283 Cipla (China) Pharmaceutical Co., Ltd Cipla (Jiangsu) Pharmaceutical Co., Ltd. Subsidiaries Any other transaction Reimbursement charges received 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 125.00 0.00 0.00
284 Cipla (China) Pharmaceutical Co., Ltd Shanghai Sage Business Consulting Co Ltd Entity related to KMP Any other transaction Professional Fees paid 500.00 Approved 169.00 0.00 0.00
285 Meditab Holdings Limited Cipla Medpro South Africa Proprietary Limited Subsidiaries Interest received 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 43.00 0.00 0.00
286 Cipla (Jiangsu) Pharmaceutical Co., Ltd. Cipla USA Inc. Subsidiaries Sale of goods or services 0.00 Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws. 7,270.00 0.00 0.00
287 Cipla Maroc SA Societe Marocaine De Cooperation Pharmaceutique (Cooper) Investing company Purchase of goods or services 6,000.00 Approved 489.00 0.00 0.00
288 Cipla Maroc SA Societe Marocaine De Cooperation Pharmaceutique (Cooper) Investing company Sale of goods or services 29,500.00 Approved 18,797.00 0.00 0.00
289 Cipla Maroc SA Jay Precision Products (India) Private Limited Related party of a subsidiary Purchase of goods or services 0.00 Not Applicable 2.00 0.00 0.00
290 Cipla (EU) Limited InvaGen Pharmaceuticals Inc. Subsidiaries Investment 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 58,975.00 0.00 0.00
291 Cipla (EU) Limited Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda Subsidiaries Investment 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 476.00 0.00 0.00
292 Cipla (EU) Limited Cipla Middle East Company Subsidiaries Investment 0.00 Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws. 5,166.00 0.00 0.00
293 Aspergen Limited Kemwell Biopharma Private Limited Private company in which a director/relative is a member/director Any other transaction Capital contribution 0.00 Not Applicable 20,240.00 0.00 0.00
294 Aspergen Limited Aspergen Inc. Subsidiaries Investment 26,875.00 Approved 20,480.00 0.00 0.00
295 Cipla Digital Health Limited Cipla Digital Health Limited Gratuity Trust Post employment benefit trust Any other transaction Payable to Gratuity Trust 0.00 Not Applicable 0.00 (5.00) 9.00
296 Jay Precision Pharmaceuticals Private Limited Jay Precision Products (India) Private Limited Private company in which a director/relative is a member/director Any other transaction Capital Advance 0.00 Not Applicable 0.00 399.00 120.00
297 Jay Precision Pharmaceuticals Private Limited Jay Precision Products (India) Private Limited Private company in which a director/relative is a member/director Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 5.00 2.00
298 Jay Precision Pharmaceuticals Private Limited Medispray Laboratories Private Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 49.00 98.00
299 Meditab Specialities Limited Meditab Specialities Limited Employees Comprehensive Gratuity Scheme Post employment benefit trust Any other transaction Payable to Gratuity Trust 0.00 Not Applicable 0.00 24.00 47.00
300 Medispray Laboratories Private Limited Cipla Maroc SA Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 838.00 1,420.00
301 Medispray Laboratories Private Limited Meditab Specialities Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 3.00 1.00
302 Medispray Laboratories Private Limited Jay Precision Products (India) Private Limited Private company in which a director/relative is a member/director Any other transaction Capital Advance 0.00 Not Applicable 0.00 2,006.00 0.00
303 Medispray Laboratories Private Limited Jay Precision Products (India) Private Limited Private company in which a director/relative is a member/director Any other transaction Trade and Other Payables 0.00 Not Applicable 0.00 0.00 1,382.00
304 Medispray Laboratories Private Limited Medispray Laboratories Private Limited Employees Comprehensive Gratuity Scheme Post employment benefit trust Any other transaction Payable to Gratuity Trust 0.00 Not Applicable 0.00 120.00 185.00
305 Goldencross Pharma Limited Cipla Health Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 0.00 97.00
306 Goldencross Pharma Limited Jay Precision Products (India) Private Limited Related Party of a Subsidary Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 0.00 6.00
307 Goldencross Pharma Limited Goldencross Pharma Limited Employees Group Gratuity Fund Post Employment Benefit Trust Any other transaction Payable to Gratuity Trust 0.00 Not Applicable 0.00 16.00 37.00
308 Sitec Labs Limited Cipla USA Inc. Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 3.00 13.00
309 Sitec Labs Limited Medispray Laboratories Private Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 3.00 4.00
310 Sitec Labs Limited Meditab Specialities Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 0.00 0.00
311 Sitec Labs Limited Cipla Health Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 0.00 0.00
312 Sitec Labs Limited Sitec Labs Private Limited Employees Comprehensive Gratuity Scheme Post employment benefit trust Any other transaction Payable to Gratuity Trust 0.00 Not Applicable 0.00 636.00 595.00
313 Cipla Health Limited Cipla Pharma and Life Sciences Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 901.00 478.00
314 Cipla Pharma and Life Sciences Limited GoApptiv Private Limited Associate of listed entity Any other transaction Trade and Other Payables 0.00 Not Applicable 0.00 18.00 1.00
315 Cipla Pharma and Life Sciences Limited Cipla Pharma and Life Sciences Limited Employees Gratuity Fund Post Employment Benefit Trust Any other transaction Payable to Gratuity Trust 0.00 Not Applicable 0.00 (51.00) 39.00
316 Meditab Holdings Limited Cipla Kenya Limited Subsidiaries Loan 0.00 Not Applicable 0.00 1,655.00 1,716.00 Loan 6.00 0 Unsecured Working Capital Textual Information(6)
317 Cipla USA Inc. Exelan Pharmaceuticals Inc. Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 0.00 300.00
318 Cipla USA Inc. Aspergen Inc. Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 144.00 191.00
319 InvaGen Pharmaceuticals Inc. Cipla USA Inc. Subsidiaries Any other transaction Trade and Other Receivable 0.00 Not Applicable 0.00 721.00 0.00
320 InvaGen Pharmaceuticals Inc. Exelan Pharmaceuticals Inc. Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 4,295.00 0.00
321 InvaGen Pharmaceuticals Inc. Cipla Therapeutics Inc. Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 2.00 4.00
322 Aspergen Inc. Kemwell Biopharma Private Limited Private company in which a director/relative is a member/director Any other transaction Trade and Other Payables 0.00 Not Applicable 0.00 7,752.00 15,179.00
323 Cipla Australia Pty Limited Cipla Gulf FZ-LLC Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 951.00 0.00
324 Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda Cipla Gulf FZ-LLC Subsidiaries Any other transaction Trade and Other Payables 0.00 Not Applicable 0.00 (371.00) 454.00
325 Cipla Europe NV CiplaRna GmbH Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 1,002.00 361.00
326 Cipla Gulf FZ – LLC Cipla Middle East Company Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 0.00 240.00
327 Cipla (Jiangsu) Pharmaceutical Co., Ltd. Cipla USA Inc. Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 9,606.00 10,851.00
328 Cipla (China) Pharmaceutical Co., Ltd Cipla (Jiangsu) Pharmaceutical Co., Ltd. Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 60.00 189.00
329 Cipla (China) Pharmaceutical Co., Ltd Shanghai Sage Business Consulting Co Ltd Entity related to KMP Any other transaction Trade and Other Payables 0.00 Not Applicable 0.00 61.00 22.00
330 Cipla (EU) Limited Cipla Europe NV Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 507.00 263.00
331 Cipla (EU) Limited Cipla (Jiangsu) Pharmaceutical Co., Ltd. Subsidiaries Loan 0.00 Not Applicable 0.00 11,854.00 11,978.00 Loan 0 1 Unsecured Working capital Textual Information(7)
332 Cipla (EU) Limited Mexicip S.A. de C.V. Subsidiaries Loan 0.00 Not Applicable 0.00 379.00 383.00 Loan 8.00 2 Unsecured Working capital
333 Cipla (EU) Limited Cipla Maroc SA Subsidiaries Any other transaction Dividend Receivable 0.00 Not Applicable 0.00 0.00 1,496.00
334 Actor Pharma Proprietary Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 1,753.00 1,931.00
335 Actor Pharma Proprietary Limited Cipla Select Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 2,326.00 2,897.00
336 Cipla Medpro Manufacturing (Pty) Limited Cipla Empowerment Trust Entities over which the company is able to exercise significant influence/Control Any other transaction Advance 0.00 Not Applicable 0.00 0.00 0.00
337 Cipla Medpro Manufacturing (Pty) Limited Cipla Empowerment Trust Entities over which the company is able to exercise significant influence/Control Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 8.00 8.00
338 Cipla Medpro Manufacturing (Pty) Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 48,062.00 52,337.00
339 Cipla Medpro Manufacturing (Pty) Limited Cipla Select Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 1,729.00 3,365.00
340 Cipla Medpro South Africa Proprietary Limited Brandmed (Pty) Limited Associate Loan 0.00 Not Applicable 0.00 2,575.00 2,854.00 Loan 0 0 Unsecured Working capital Textual Information(8)
341 Cipla Medpro South Africa Proprietary Limited Cipla Medpro Manufacturing (Pty) Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 4,154.00 430.00
342 Cipla Medpro South Africa Proprietary Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Loan 0.00 Not Applicable 0.00 48,598.00 51,458.00 Loan 0 0 Unsecured Working capital Textual Information(9)
343 Cipla Select Proprietary Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 69.00 374.00
344 Cipla-Medpro (Pty) Limited Cipla Select Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 194.00 408.00
345 Medpro Pharmaceutica (Pty) Limited Cipla Medpro Manufacturing (Pty) Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 57,304.00 35,806.00
346 Medpro Pharmaceutica (Pty) Limited Cipla Medpro Manufacturing (Pty) Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 174.00 185.00
347 Medpro Pharmaceutica (Pty) Limited Cipla Medpro South Africa Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 37,188.00 31,281.00
348 Medpro Pharmaceutica (Pty) Limited Cipla Select Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 2,908.00 1,893.00
349 Medpro Pharmaceutica (Pty) Limited Cipla Select Proprietary Limited Subsidiaries Any other transaction Trade and Other Payables 0.00 Not Applicable 0.00 1,828.00 3,304.00
350 Medpro Pharmaceutica (Pty) Limited Cipla Kenya Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 3,127.00 3,294.00
351 Medpro Pharmaceutica (Pty) Limited Cipla-Medpro Distribution Centre Proprietary Limited Subsidiaries Any other transaction Trade and Other Payables 0.00 Not Applicable 0.00 1,082.00 1,173.00
352 Medpro Pharmaceutica (Pty) Limited Cipla-Medpro (Pty) Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 (193.00) 682.00
353 Medpro Pharmaceutica (Pty) Limited Mirren Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 5,975.00 4,588.00
354 Mirren Proprietary Limited Cipla Medpro Manufacturing (Pty) Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 116.00 119.00
355 Mirren Proprietary Limited Medpro Pharmaceutica (Pty) Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 3,137.00 1,766.00
356 Cipla Maroc SA Societe Marocaine De Cooperation Pharmaceutique (Cooper) Investing company Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 7,326.00 8,871.00
357 Cipla Maroc SA Societe Marocaine De Cooperation Pharmaceutique (Cooper) Investing company Any other transaction Interest Payable 0.00 Not Applicable 0.00 62.00 0.00
358 Cipla (EU) Limited CiplaRna GmbH Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 13.00 0.00
359 Cipla Holding B.V. Cipla Europe NV Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 441.00 743.00
360 Cipla Holding B.V. Cipla (EU) Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 490.00 345.00
361 Cipla Health Limited Cipla Health Limited Employees Gratuity Scheme Post employment benefit trust Any other transaction Payable to Gratuity Trust 0.00 Not Applicable 0.00 260.00 113.00
362 Jay Precision Pharmaceuticals Private Limited Cipla Maroc SA Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 45.00 0.00
363 Cipla (EU) Limited Cipla (Jiangsu) Pharmaceutical Co., Ltd. Subsidiaries Any other transaction Interest Receivable 0.00 Not Applicable 0.00 2,445.00 2,828.00
364 Cipla Medpro Botswana Proprietary Limited Medpro Pharmaceutica Proprietary Limited Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 0.00 0.00
365 Jay Precision Pharmaceuticals Private Limited Jay Precision Pharmaceuticals Employees Group Gratuity Trust Post employment benefit trust Any other transaction Payable to Gratuity Trust 0.00 Not Applicable 0.00 43.00 3.00
366 Cipla USA Inc. InvaGen Pharmaceuticals Inc. Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 0.00 16,471.00
367 Exelan Pharmaceuticals Inc. InvaGen Pharmaceuticals Inc. Subsidiaries Any other transaction Trade and Other Receivables 0.00 Not Applicable 0.00 0.00 19,695.00
Total value of transaction during the reporting period 7,66,277.00



Text Block

Textual Information(1) Interest Rate : 250 bps higher than 3 months JIBAR rate Tenure: Repayable by 31st October 2029
Textual Information(2) Interest Rate : Term SOFR + 150 bps Tenure: Repayable by 24th March 2028
Textual Information(3) Interest Rate : 6.5%-7.5% Tenure: Repayable by 21st September 2027
Textual Information(4) Tenure: Repayable by 6th November, 2030
Textual Information(5) Tenure: Repayable by 30th August 2032
Textual Information(6) Tenure : Repayable on Demand
Textual Information(7) Interest Rate : 4% to 6%
Textual Information(8) Interest Rate : South African prime rate less 1.75% Tenure: Repayment to start from 31 March 2025 to 31 March 2028
Textual Information(9) Interest Rate : 275 bps higher than 3 months JIBAR rate capped at the prime lending rate in South Africa Tenure: Repayament starts with 31 March 2026 to Oct 2029